Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South America mulls centralized price negotiations for hep C drugs

This article was originally published in Scrip

Executive Summary

Members of UNASUR, the Union of South American Nations, could combine their bargaining power to drive down the price of the new hepatitis C drugs, such as Gilead's Sovaldi. If successful, such a move could set an uncomfortable precedent for drug companies selling expensive new drugs in the region.

You may also be interested in...



Brazil Authorizes Oxford/AZ and Sinovac Vaccines

In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.

Success For Dutch Parallel Registration and Reimbursement Pilot

A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.

Constitutional Complaints In Germany Cast Doubt Over Fate Of UPC

The UK’s withdrawal from the EU could upset the Unitary Patent Court project.

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel